Loading...
•
Dec 31, 2023
Zevra Q4 2023 Earnings Report
Reported financial results for the fourth quarter and year ended December 31, 2023.
Key Takeaways
Zevra Therapeutics reported Q4 2023 net revenue of $13.2 million. The company is focusing on the launch of OLPRUVA, preparing for the launch of arimoclomol, and advancing the KP1077 development program.
Completed the acquisition of Acer Therapeutics, Inc.
OLPRUVA commercial launch is underway with a focus on centers of excellence and a Quick Start program.
Submitted a comprehensive data set to FDA supporting its resubmission of the New Drug Application (NDA) for arimoclomol.
Reported positive topline data from its Phase 2 study of KP1077 in patients with IH.
Forward Guidance
Zevra's cash runway is expected to extend into 2026, including revenue from OLPRUVA sales, arimoclomol reimbursements, and investments in commercial activities.
Positive Outlook
- Revenue from expected sales of OLPRUVA
- Ongoing reimbursements from the French EAP for arimoclomol
- Investments into the incremental commercial activities needed to support the launch of arimoclomol, if approved
- Completion of the KP1077 development program for IH
- Potential FDA approval of arimoclomol
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...